In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Takeda's final offer for Shire PLC stands; £46bn merger creates new top ten pharmaco

Executive Summary

Following over a month of back and forth and four rejected offers, Shire PLC finally accepted a merger bid from Takeda Pharmaceutical Co. Ltd. The deal, which values Shire at about £46bn ($61.2bn; enterprise value of close to $80bn, including net debt), consists of $30.33 in cash and 0.839 of a new Takeda share or 1.678 Takeda ADSs for each outstanding Shire share, for an implied value per Shire share of £49.01 and a total of 44% cash and 56% equity.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies